MCP-1 and MIP-1α Biomarkers for CPPS Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for chronic pelvic pain syndrome (CPPS) lack objective criteria, leading to misdiagnosis and unnecessary antibiotic treatments, with no clear consensus on its etiology or effective diagnostic tools.
Innovation Solution
The use of MCP-1 and MIP-1α as biomarkers for detecting chronic pelvic pain syndrome through methods involving mRNA detection using nucleic acid probes or antibody binding to polypeptides in samples such as semen or expressed prostatic secretions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods for CPPS are used, then diagnosis can be performed, but misdiagnosis occurs and unnecessary antibiotic treatments are prescribed due to lack of objective criteria
Solution Approach 1:
The invention changes the diagnostic parameter from subjective symptom assessment to objective molecular biomarker detection. By measuring cytokine levels (IL-8, MCP-1, MIP-1α) in prostatic secretions, the diagnosis transitions from unreliable clinical judgment to precise quantitative measurement, resolving the contradiction between diagnostic capability and diagnostic accuracy.
Solution Approach 2:
The invention introduces molecular biomarkers (cytokines IL-8, MCP-1, MIP-1α) as intermediary substances that mediate between the disease state and diagnostic detection. These biomarkers serve as objective indicators that bridge the gap between subjective symptoms and reliable diagnosis, enabling accurate differentiation of CPPS subtypes without misdiagnosis.
2Ease of operation
If CPPS is misdiagnosed as bacterial prostatitis, then treatment decisions are made, but unnecessary antibiotic courses are administered with no demonstrated benefit
Solution Approach 1:
The invention performs preliminary diagnostic action by detecting cytokine biomarkers before initiating treatment. This preliminary molecular assessment identifies the true etiology (inflammatory vs. non-inflammatory CPPS) before treatment decisions are made, preventing unnecessary antibiotic administration and enabling targeted therapy selection in advance.
Solution Approach 2:
The invention establishes feedback through objective biomarker measurement that informs treatment decisions. By measuring cytokine levels in prostatic secretions, the system provides real-time feedback on the inflammatory status, allowing clinicians to adjust treatment protocols based on actual disease characteristics rather than proceeding with routine antibiotic therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides an objective means for diagnosing CPPS, enabling accurate identification and monitoring, potentially reducing unnecessary treatments and improving therapeutic decision-making.
Implementation Method 1
detecting the expression of MCP-1 and/or MIP-1α comprises detecting the presence of MCP-1 and/or MIP-1α mRNA. In some embodiments, detecting expression of MCP-1 and/or MIP-1α mRNA comprises exposing the MCP-1 and/or MIP-1α mRNA to a nucleic acid probe complementary to the MCP-1 and/or MIP-1α mRNA.
Implementation Method 2
detecting the presence of a MCP-1 and/or MIP-1α polypeptide comprises exposing the MCP-1 and/or MIP-1α polypeptide to an antibody specific to the MCP-1 and/or MIP-1α polypeptide and detecting the binding of the antibody to the MCP-1 and/or MIP-1α polypeptide.
Data Source
AI summary
The present invention provides biomarkers of chronic pelvic pain syndrome for use in diagnosis, drug screening, therapy monitoring, research and therapeutic applications. In particular, the present invention provides MCP-1 and MIP-1α as biomarkers of chronic pelvic pain syndrome.